PERK5 Antibody

Definition and Biological Role of ERK5 Antibodies

ERK5 antibodies are immunological reagents designed to detect ERK5 (MAPK7) or its activated, phosphorylated form (pERK5 at Thr218/Tyr220). These antibodies enable researchers to:

• Quantify ERK5 expression in tissues or cell lines via Western blot (WB), immunohistochemistry (IHC), or immunofluorescence (IF) .

• Assess ERK5 activation status by targeting its dually phosphorylated motif (Thr218/Tyr220), a hallmark of kinase activity .

• Study ERK5's role in cell proliferation, survival, and cancer progression .

Detection of ERK5 in Cancer Studies

• Breast Cancer: ERK5 overexpression correlates with poor prognosis. In a cohort of 84 breast cancer patients, high ERK5 levels were an independent predictor of reduced disease-free survival (HR = 2.1, p < 0.01) . pERK5 was detected in aggressive triple-negative breast cancer (TNBC) cell lines, showing extranuclear localization linked to metastasis .

• Lung Cancer: ERK5 knockdown reduced proliferation in non-small cell lung cancer (NSCLC) cells (p < 0.05) and sensitized tumors to cisplatin .

Technical Validation

• Specificity: Anti-pERK5 antibodies (e.g., #3371) were validated using ERK5-depleted cells and peptide-blocking assays to confirm minimal cross-reactivity with ERK1/2 .

• Assay Kits: The MSD MULTI-ARRAY Phospho-ERK5 Assay quantifies pERK5 in lysates with high sensitivity (detection limit: 0.5 µg/mL) .

Table 2: ERK5 as a Prognostic Marker in Human Cancers

Mechanistic Insights from ERK5 Inhibition

• Proliferation: ERK5 knockdown via shRNA reduced breast cancer cell growth by 40–60% and enhanced trastuzumab efficacy .

• Therapeutic Targeting: Pharmacological inhibition of ERK5 synergized with anti-HER2 therapies and reversed drug resistance in preclinical models .

Limitations and Future Directions

• Technical Challenges: pERK5 detection in patient samples requires fresh tissue and standardized protocols, limiting clinical adoption .

• Therapeutic Potential: Small-molecule ERK5 inhibitors (e.g., BIX02189) show promise in preclinical studies but await clinical validation .